Question · Q3 2022
Shubhendu Sen Roy of Brookline Capital Markets questioned if the increased enrollment in the FURI study would impact financials, how the additional patient data would be utilized, whether certain indications within the FURI trial showed better responses, and asked for the data timeline for the SCYNERGIA study.
Answer
President & CEO Dr. Marco Taglietti explained that the incremental cost for additional FURI patients is minimal and the decision was made to maintain strong investigator relationships. Chief Medical Officer Dr. David Angulo stated that all data from FURI and CARES will be analyzed together and compared against external controls to support a salvage therapy indication. He noted that gist infections, like Candida, are expected to show the best response, aligning with the drug's mechanism. Dr. Angulo also confirmed that data from the SCYNERGIA study is expected in the first half of 2023.